International Majors Invest 170 Million NOK in Norwegian Hydrogen Mem-Tech
10.5.2022 13:01:00 EEST | Business Wire | Press release
AP Ventures, Yara Growth Ventures, Shell Ventures, Saudi Aramco Energy Ventures and SINTEF Venture are putting their trust and investment into Hydrogen Mem-Tech (HMT). HMT´s palladium membrane technology separates hydrogen from bio and natural gas.
"We are proud and incredibly humbled to have secured what will be one of the largest capital investments in an early-stage Norwegian tech company in recent years”, says Thomas Reinertsen, CEO of Hydrogen Mem-Tech.
The company has developed a technology where clean hydrogen is produced from bio and natural gas, while CO2 and other residual gases are captured to be utilized or sequestered. The HMT palladium membrane technology builds on more than 20 years of research from SINTEF, and it has been extensively tested and piloted over several years.
“We are very pleased to have secured investors with a strong mix of industrial and financial expertise. I´m certain that our new investors will help deploy our technology out into the world.” said Thor Egil Five, Chairman of the board at Hydrogen Mem-Tech.
“We are delighted to have led the investment round for Hydrogen Mem-Tech with a strong group of co-investors. As an established investor in the hydrogen value chain, we understand the exciting potential of this technology to unlock decarbonization opportunities across hard to abate industry and mobility.” said Andrew Hinkly, Managing Partner at AP Ventures.
Yara´s investment company for start-ups, ‘Yara Growth Ventures’, are among the new investors.
“We believe that this promising technology developed in Norway will contribute to trigger new Norwegian industry and help increase the use of hydrogen and ammonia. This is one of several investments we plan to make in Norway”, says Stian Nygaard, Investment Director at Yara Growth Ventures.
“As a company, we have an ambition to accelerate the hydrogen economy. HMT’s technology enables the adoption of hydrogen and ammonia and fuels the progress society needs for a cleaner energy future. We are excited to help them take the next steps and explore the many potential applications across industries”, said Bilal Ahmad, Venture Principal at Shell Ventures.
“For Saudi Aramco Energy Ventures this investment into HMT is very strategic. Hydrogen and carbon capture technologies are of the highest importance to Aramco, and we look forward to working with HMT to use their unique gas separation membranes and realizing the benefits they bring”, says Richard Riggs, Investment Director at Saudi Aramco Energy Ventures.
“We are very happy to be able to partner with this highly respected and professional venture investor group to bring HMT one step closer to commercial success. The technology behind the technology is licensed from SINTEF and our investment in HMT supports our key mandate - Technology for a better society, where we invest in companies with SINTEF based technology.” says Asle Jostein Hovda, Investment Director at SINTEF Venture.
Read more at: https://hydrogen-mem-tech.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005726/en/
Contact information
Thomas Reinertsen, CEO
(+47) 930 90 494
thomas.reinertsen@hydrogen-mem-tech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio ® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis30.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label extension study in adults and adolescents with moderate-to-severe atopic dermatitis’, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, on Thursday, October 1, from 10:45-10:55 AM CET in Hall N by Dr. Matthias Augustin, an ARCADIA clinical trial investigator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929663019/en/ “These three-year data provide important evi
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill30.9.2026 08:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from threePhase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zasocitinib’s superior efficacy compared to deucravacitinib and reinforce the potential for zasocitinib to deliver rapid, durable and consistent skin clearance in a convenient once-daily pill.2-5 “Psoriasis is a heterogeneous disease driven by multiple immune pathways and TYK2 plays a central role in regulating several key inflammatory signals,” said Chinwe Ukomadu, M.D., Ph.D., Senior Vice President and Head, Gastrointestinal & Inflammation Therapeutic Area Unit at Takeda. “Across our Phase 3 trials, zasocitinib demonstrated superiority versus two distinct oral thera
Ant International’s Antom Supports Google Gemini in Expanding Access to AI Service in Asia30.9.2026 07:16:00 EEST | Press release
Google Gemini and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership to make AI tools for learning, creativity and productivity more accessible to users in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929520038/en/ Google AI Plus free trial offers are available in select digital payment and retail channels partnering with A+Rewards in Indonesia, with more markets to follow. Promoting Google AI Plus through AI-powered growth engine The collaboration will leverage A+Rewards, Antom’s digital marketing solution powered by privacy-preserving computing and AI technologies, and its extensive partner network of digital payment apps, e-commerce platforms and lifestyle service providers, to help expand access to Google AI Plus. Integrated into more than 30 leading digital platform partners, A+ Rewards provides in-app entry points where users
Signaloid Joins CERN openlab's Heterogeneous Architectures Testbed to Explore the Future of Scientific Computing30.9.2026 07:00:00 EEST | Press release
British computing company Signaloid has joined CERN openlab, the public-private partnership through which CERN evaluates emerging information technologies for scientific computing. As part of the collaboration, CERN and Signaloid will evaluate Signaloid's distribution-extended compute hardware (UxHw®) technology within the CERN openlab Heterogeneous Architectures Testbed, which explores new processor technologies for future scientific computing infrastructures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929985154/en/ Signaloid joins CERN openlab: Putting Signaloid's UxHw® Technology to the Test at the World's Largest Particle Collider The collaboration comes as research organisations worldwide are increasingly adopting heterogeneous computing architectures that combine CPUs, GPUs and specialised accelerators to tackle demanding workloads more efficiently. As the High-Luminosity Large Hadron Collider (HiLumi LHC) appro
FPT Named in Forrester’s The SAP Services Landscape Report30.9.2026 06:00:00 EEST | Press release
Global technology corporation FPT has been included among the notable providers in The SAP Services Landscape, Q3 2026, published by Forrester Research, Inc. The report provides an overview of SAP services providers, examining their market focus, geographic presence, and business specializations to support enterprises in evaluating potential technology partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929359531/en/ The report includes FPT as a systems integrator with an Asia Pacific geographic focus and an industry focus spanning financial services and insurance, healthcare, and manufacturing. FPT identified SAP Business Data Cloud, SAP Enterprise Resource Planning (ERP), and SAP Supply Chain Management (SCM) as its three primary extended business scenario focus areas, what FPT believes reflects its emphasis on modernizing core enterprise systems and enabling more integrated, data-driven operations. Building on mor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom